Who are Propranolol LA's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): tafluprost and dorzolamide/timolol, Brimonidine/Timolol mixed combination, Dorzolamide-timolol and latanoprost, topical Timolol maleate 0.5% eye drops, oral Propranolol, treatment with brimonidine/timolol.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/propranolol-la.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Propranolol LA — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Propranolol LA (Propranolol LA) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Non-selective beta-adrenergic antagonist. Area: Cardiovascular.

phase 3 Non-selective beta-adrenergic antagonist Beta-1 and beta-2 adrenergic receptors Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Propranolol LA (Propranolol LA) — MetroHealth Medical Center. Propranolol is a non-selective beta-adrenergic receptor antagonist that blocks the effects of epinephrine and norepinephrine on the heart and blood vessels.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Propranolol LA TARGET	Propranolol LA	MetroHealth Medical Center	phase 3	Non-selective beta-adrenergic antagonist	Beta-1 and beta-2 adrenergic receptors
tafluprost and dorzolamide/timolol	tafluprost and dorzolamide/timolol	Aristotle University Of Thessaloniki	marketed	Prostaglandin analogue / carbonic anhydrase inhibitor / beta-blocker combination	Prostaglandin F receptor (FP receptor), carbonic anhydrase II, beta-1 and beta-2 adrenergic receptors
Brimonidine/Timolol mixed combination	Brimonidine/Timolol mixed combination	Seoul National University Hospital	marketed	Alpha-2 adrenergic agonist / Beta-blocker combination	Alpha-2 adrenergic receptor; Beta-1 and Beta-2 adrenergic receptors
Dorzolamide-timolol and latanoprost	Dorzolamide-timolol and latanoprost	Laboratorios Sophia S.A de C.V.	marketed	Fixed-dose combination of carbonic anhydrase inhibitor, beta-blocker, and prostaglandin F analog	Carbonic anhydrase II (dorzolamide), beta-1 and beta-2 adrenergic receptors (timolol), prostaglandin F receptor (latanoprost)
topical Timolol maleate 0.5% eye drops	topical Timolol maleate 0.5% eye drops	Ain Shams University	marketed	Beta-adrenergic antagonist (non-selective)	Beta-1 and beta-2 adrenergic receptors
oral Propranolol	oral Propranolol	Ahmed talaat ahmed aly	marketed	Non-selective beta-adrenergic antagonist (beta-blocker)	Beta-1 and beta-2 adrenergic receptors
treatment with brimonidine/timolol	treatment with brimonidine/timolol	Aristotle University Of Thessaloniki	marketed	Alpha-2 adrenergic agonist / Beta-blocker combination	Alpha-2 adrenergic receptor; Beta-1 and Beta-2 adrenergic receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Non-selective beta-adrenergic antagonist class)

Allergan · 1 drug in this class
Merck Sharp & Dohme LLC · 1 drug in this class
MetroHealth Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Propranolol LA — Competitive Intelligence Brief. https://druglandscape.com/ci/propranolol-la. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing